To investigate the HH pathway in which ARP-T1 plays a role in BCC onset, differentiated NHEK cells, in which ARP-T1 is highly expressed, were treated with different kinase inhibitors. This evidence concerns the gene ACTRT1 and skin basal cell carcinoma.